Mycoplasma pneumoniae in children: Carriage, pathogenesis, and antibiotic resistance

Current Opinion in Infectious Diseases

Volumn 27, Issue 3, 2014, Pages 220-227

  Meyer Sauteur, Patrick M ^a   Van Rossum, Annemarie M C ^a   Vink, Cornelis ^a,b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

carriage; children; diagnosis; macrolide resistance; Mycoplasma pneumoniae

Indexed keywords

BETA LACTAM ANTIBIOTIC; MACROLIDE; PNEUMOCOCCUS VACCINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBODY RESPONSE; ASTHMA; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; BRONCHITIS; CHILDHOOD DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC PROCEDURE; DISEASE CARRIER; DRUG EFFICACY; EPIDEMIC; FEVER; HUMAN; MACROLIDE RESISTANT MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; PATHOGENESIS; PHARYNGITIS; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY TRACT INFECTION; REVIEW; SEROLOGY; THORAX PAIN; CHILD; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOPHYSIOLOGY; PRESCHOOL CHILD; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MYCOPLASMA PNEUMONIAE; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 84900501387     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000063     Document Type: Review

References (53)

1. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004; 17:697-728; table of contents.
2. Principi N, Esposito S. Emerging role of Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric respiratory-tract infections. Lancet Infect Dis 2001; 1:334-344.
3. Narita M. Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special reference to pneumonia. J Infect Chemother 2010; 16:162-169.
4. Spuesens EB, Fraaij PL, Visser EG, et al. Carriage of Mycoplasma pneumo-niae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med 2013; 10:e1001444.
5. Wood PR, Hill VL, Burks ML, et al. Mycoplasma pneumoniae in children with acute and refractory asthma. Ann Allergy Asthma Immunol 2013; 110:328-334e1.
6. Wang K, Gill P, Perera R, et al. Clinical symptoms and signs for the diagnosis of Mycoplasma pneumoniae in children and adolescents with community-acquired pneumonia. Cochrane Database Syst Rev 2012;10:CD009175.
7. Principi N, Esposito S. Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection. J Antimicrob Chemother 2013; 68:506-511.
8. Jacobs E. Mycoplasma pneumoniae: now in the focus of clinicians and epidemiologists. Euro Surveill 2012; 17:1-3.
9. Polkowska A, Harjunpaa A, Toikkanen S, et al. Increased incidence of Mycoplasma pneumoniae infection in Finland, 2010-2011. Euro Surveill 2012; 17:pii: 20072.
10. Foy HM. Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients. Clin Infect Dis 1993; 17 (Suppl 1): S37-46.
11. Centers for Disease Control and Prevention (CDC). Mycoplasma pneumo-niae outbreak at a university-Georgia, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:603-606.
12. Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 2004; 113:701-707.
13. Baer G, Engelcke G, Abele-Horn M, et al. Role of Chlamydia pneumoniae and Mycoplasma pneumoniae as causative agents of community-acquired pneumonia in hospitalised children and adolescents. Eur J Clin Microbiol Infect Dis 2003; 22:742-745.
14. Principi N, Esposito S, Blasi F, et al. Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections. Clin Infect Dis 2001; 32:1281-1289.
15. Fischer JE, Steiner F, Zucol F, et al. Use of simple heuristics to target macrolide prescription in children with community-acquired pneumonia. Arch Pediatr Adolesc Med 2002; 156:1005-1008.
16. Kannan TR, Baseman JB. ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens. Proc Natl Acad Sci U S A 2006; 103: 6724-6729.
17. Meyer Sauteur PM, Jacobs BC, Spuesens EBM, et al. Antibody responses to Mycoplasma pneumoniae: role in pathogenesis and diagnosis of encepha litis? PLoS Pathog 2014 (in press).
18. Atkinson TP. Is asthma an infectious disease? New evidence. Curr Allergy Asthma Rep 2013; 13:702-709.
19. Smith-Norowitz TA, Silverberg JI, Kusonruksa M, et al. Asthmatic children have increased specific anti-Mycoplasma pneumoniae IgM but not IgG or IgE-values independent of history of respiratory tract infection. Pediatr Infect Dis J 2013; 32:599-603.
20. Bebear C, Raherison C, Nacka F, et al. Comparison of Mycoplasma pneumoniae infections in asthmatic children versus asthmatic adults. Pediatr Infect Dis J 2013; 33:e71-e75.
21. Atkinson TP, Duffy LB, Pendley D, et al. Deficient immune response to Mycoplasma pneumoniae in childhood asthma. Allergy Asthma Proc 2009; 30:158-165.
22. Medina JL, Coalson JJ, Brooks EG, et al. Mycoplasma pneumoniae CARDS toxin induces pulmonary eosinophilic and lymphocytic inflammation. Am J Respir Cell Mol Biol 2012; 46:815-822.
23. Hardy RD, Coalson JJ, Peters J, et al. Analysis of pulmonary inflammation and function in the mouse and baboon after exposure to Mycoplasma pneumoniae CARDS toxin. PLoS One 2009; 4:e7562.
24. Schalock PC, Dinulos JG. Mycoplasma pneumoniae-induced cutaneous disease. Int J Dermatol 2009; 48:673-680; quiz 680-681.
25. Meyer Sauteur PM, Goetschel P, Lautenschlager S. Mycoplasma pneumo-niae and mucositis-part of the Stevens-Johnson syndrome spectrum. J Dtsch Dermatol Ges 2012; 10:740-746.
26. Bitnun A, Ford-Jones EL, Petric M, et al. Acute childhood encephalitis and Mycoplasma pneumoniae. Clin Infect Dis 2001; 32:1674-1684.
27. Sinha S, Prasad KN, Jain D, et al. Preceding infections and antiganglio-side antibodies in patients with Guillain-Barré syndrome: a single centre prospective case-control study. Clin Microbiol Infect 2007; 13:334-337.
28. Riordan A. In children with respiratory symptoms are Mycoplasma pneumo-niae PCR and serology clinically significant? Arch Dis Child Educ Pract Ed 2014. [Epub ahead of print]
29. Loens K, Goossens H, Ieven M. Acute respiratory infection due to Myco-plasma pneumoniae: current status of diagnostic methods. Eur J Clin Micro-biol Infect Dis 2010; 29:1055-1069.
30. Waites KB, Duffy LB, Bebear CM, et al. Standardized methods and quality control limits for agar and broth microdilution susceptibility testing of Myco-plasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum. J Clin Microbiol 2012; 50:3542-3547.
31. Dumke R, Strubel A, Cyncynatus C, et al. Optimized serodiagnosis of Mycoplasma pneumoniae infections. Diagn Microbiol Infect Dis 2012; 73:200-203.
32. Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25-e76.
33. Mulholland S, Gavranich JB, Chang AB. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Rev 2010; 7:CD004875.
34. Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011; 66 (Suppl 2):ii1-ii23.
35. Spuesens EBM, Meyer Sauteur PM, Vink C, et al. Mycoplasma pneumoniae infections: does treatment help? J Infect 2014 (in press).
36. Bebear C, Pereyre S, Peuchant O. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiol 2011; 6:423-431.
37. Liu Y, Ye X, Zhang H, et al. Multiclonal origin of macrolide-resistant Mycoplasma pneumoniae isolates as determined by multilocus variable-number tandem-repeat analysis. J Clin Microbiol 2012; 50:2793-2795.
38. Pereyre S, Charron A, Hidalgo-Grass C, et al. The spread of Mycoplasma pneumoniae is polyclonal in both an endemic setting in France and in an epidemic setting in Israel. PLoS One 2012; 7:e38585.
39. Chironna M, Sallustio A, Esposito S, et al. Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children. J Antimicrob Chemother 2011; 66:734-737.
40. Cardinale F, Chironna M, Dumke R, et al. Macrolide-resistant Mycoplas-ma pneumoniae in paediatric pneumonia. Eur Respir J 2011; 37:1522-1524.
41. Saegeman V, Proesmans M, Dumke R. Management of macrolide-resistant Mycoplasma pneumoniae infection. Pediatr Infect Dis J 2012; 31:1210-1211.
42. Zhao F, Liu G, Wu J, et al. Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012. Antimicrob Agents Chemother 2013; 57:1521-1523.
43. Hong KB, Choi EH, Lee HJ, et al. Macrolide resistance of Mycoplasma pneumoniae, South Korea, 2000-2011. Emerg Infect Dis 2013; 19:1281-1284.
44. Zhou Y, Zhang Y, Sheng Y, et al. More complications occurred in macrolide-resistant Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother 2014; 58:1034-1038.
45. Miyashita N, Akaike H, Teranishi H, et al. Macrolide-resistant Mycoplasma pneumoniae pneumonia in adolescents and adults: clinical findings, drug susceptibility, and therapeutic efficacy. Antimicrob Agents Chemother 2013;57:5181-5185.
46. Cardinale F, Chironna M, Chinellato I, et al. Clinical relevance of Mycoplasma pneumoniae macrolide resistance in children. J Clin Microbiol 2013; 51:723-724.
47. Matsuda K, Narita M, Sera N, et al. Gene and cytokine profile analysis of macrolide-resistant Mycoplasma pneumoniae infection in Fukuoka, Japan. BMC Infect Dis 2013; 13:591.
48. Lung DC, Yip EK, Lam DS, et al. Rapid defervescence after doxycycline treatment of macrolide-resistant Mycoplasma pneumoniae associated community-acquired pneumonia in children. Pediatr Infect Dis J 2013; 32:1396-1399.
49. Okada T, Morozumi M, Tajima T, et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis 2012; 55:1642-1649.
50. Sun R, Wang L. Inhibition of Mycoplasma pneumoniae growth by FDA-approved anticancer and antiviral nucleoside and nucleobase analogs. BMC Microbiol 2013; 13:184.
51. Linchevski I, Klement E, Nir-Paz R. Mycoplasma pneumoniae vaccine protective efficacy and adverse reactions: systematic review and meta-analysis. Vaccine 2009; 27:2437-2446.
52. Zhu C, Wu Y, Chen S, et al. Protective immune responses in mice induced by intramuscular and intranasal immunization with a Mycoplasma pneumoniae P1C DNA vaccine. Can J Microbiol 2012; 58:644-652.
53. Hausner M, Schamberger A, Naumann W, et al. Development of protective anti-Mycoplasma pneumoniae antibodies after immunization of guinea pigs with the combination of a P1-P30 chimeric recombinant protein and chitosan. Microb Pathog 2013; 64:23-32.